Blood samples were obtained on admission from 2081 patients with acute
chest pain and either ST-segment depression or
troponin elevation who were included in the Global Utilization of Strategies to Open Occluded Arteries (GUSTO)-IV Non-ST-Elevation
Acute Coronary Syndrome trial and from a matching cohort of 429 apparently healthy individuals.
GDF-15 levels were determined by immunoradiometric assay. Approximately two thirds of patients presented with
GDF-15 levels above the upper limit of normal in healthy controls (1200 ng/L); one third presented with levels >1800 ng/L. Increasing tertiles of
GDF-15 were associated with an enhanced risk of death at 1 year (1.5%, 5.0%, and 14.1%; P<0.001). By multiple Cox regression analysis, only the levels of
GDF-15 and N-terminal pro-
B-type natriuretic peptide, together with age and a history of previous
myocardial infarction, contributed independently to 1-year mortality risk. Receiver operating characteristic curve analyses further illustrated that
GDF-15 is a strong marker of 1-year mortality risk (area under the curve, 0.757; best cutoff, 1808 ng/L). At this cutoff value,
GDF-15 added significant prognostic information in patient subgroups defined by age; gender; time from symptom onset to admission; cardiovascular risk factors; previous
cardiovascular disease; and the risk markers ST-segment depression,
troponin T, N-terminal pro-
B-type natriuretic peptide,
C-reactive protein, and
creatinine clearance.
CONCLUSIONS: